NOVO NORDISK A S NVO

Latest FY: 2025 Healthcare Drug Manufacturers - General
Market Price $45.89
Market Cap $207.01B
P/E Ratio N/A
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑6.4% YoY
$309.06B
3-Yr CAGR: 20.4%
Net Income ↑2.6% YoY
$130.54B
Net Margin: 42.2%
Free Cash Flow ↓-29.7% YoY
-$58.74B
FCF Yield: -28.38%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity Efficiency
67.3%
ROA: 24.0%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (NVO)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $111,780.0M $94,597.0M $47,798.0M $114.0M
FY 2017 $111,696.0M -0.1% $94,064.0M $48,680.0M +1.8% $101.0M $-7,525.0M
FY 2018 $111,831.0M +0.1% $94,214.0M $47,615.0M -2.2% $51.0M $-9,585.0M -27.4%
FY 2019 $122,021.0M +9.1% $101,933.0M $48,553.0M +2.0% $64.0M $-8,868.0M +7.5%
FY 2020 $126,946.0M +4.0% $106,014.0M $53,130.0M +9.4% $100.0M $-5,725.0M +35.4%
FY 2021 $140,800.0M +10.9% $117,142.0M $59,080.0M +11.2% $241.0M $-6,094.0M -6.4%
FY 2022 $176,954.0M +25.7% $148,506.0M $69,062.0M +16.9% $276.0M $-11,870.0M -94.8%
FY 2023 $232,261.0M +31.3% $196,496.0M $104,674.0M +51.6% $1,072.0M $-24,734.0M -108.4%
FY 2024 $290,403.0M +25.0% $245,881.0M $127,191.0M +21.5% $1,884.0M $-45,280.0M -83.1%
FY 2025 $309,064.0M +6.4% $250,276.0M $130,540.0M +2.6% $1,398.0M $-58,742.0M -29.7%
$

Valuation

Market Price $45.89
Market Cap $207.01B
Enterprise Value N/A
P/E Ratio N/A
P/B Ratio 1.05
FCF Yield -28.38%
Dividend Yield N/A
Shares Outstanding 4,429,925,500
%

Profitability & Margins

Gross Margin 80.98%
Operating Margin 41.30%
Net Margin 42.24%
Return on Equity (ROE) 67.27%
Return on Assets (ROA) 24.04%
Asset Turnover 0.57x
Revenue 3-Yr CAGR 20.43%
🛡️

Financial Health & Liquidity

Current Ratio 0.58
Cash Ratio N/A
Debt / Equity N/A
Debt / Assets N/A
Cash & Equivalents N/A
Total Debt N/A
Book Value / Share $43.80
💧

Cash Flow Efficiency

Operating Cash Flow $1.40B
Capital Expenditures (CapEx) $60.14B
Free Cash Flow -$58.74B
OCF / Revenue 0.45%
FCF / Revenue -19.01%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) N/A
EPS (Basic) N/A
Dividends / Share N/A
Book Value / Share $43.80
EPS YoY Growth N/A
🏛️

Balance Sheet (FY 2025)

Total Assets $542.90B
Total Liabilities $348.86B
Stockholders' Equity $194.05B
Current Assets $4.85B
Current Liabilities $8.42B